» Articles » PMID: 36185750

Cytokine Nanosponges Suppressing Overactive Macrophages and Dampening Systematic Cytokine Storm for the Treatment of Hemophagocytic Lymphohistiocytosis

Overview
Journal Bioact Mater
Date 2022 Oct 3
PMID 36185750
Authors
Affiliations
Soon will be listed here.
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a highly fatal condition with the positive feedback loop between continued immune cell activation and cytokine storm as the core mechanism to mediate multiple organ dysfunction. Inspired by macrophage membranes harbor the receptors with special high affinity for proinflammation cytokines, lipopolysaccharide (LPS)-stimulated macrophage membrane-coated nanoparticles (LMNP) were developed to show strong sponge ability to both IFN-γ and IL-6 and suppressed overactivation of macrophages by inhibiting JAK/STAT signaling pathway both and . Besides, LMNP also efficiently alleviated HLH-related symptoms including cytopenia, hepatosplenomegaly and hepatorenal dysfunction and save the life of mouse models. Furthermore, its sponge effect also worked well for five human HLH samples . Altogether, it's firstly demonstrated that biocompatible LMNP could dampen HLH with high potential for clinical transformation, which also provided alternative insights for the treatment of other cytokine storm-mediated pathologic conditions such as COVID-19 infection and cytokine releasing syndrome during CAR-T therapy.

Citing Articles

Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment.

Kang X, Mita N, Zhou L, Wu S, Yue Z, Jayachandra Babu R Pharmaceutics. 2024; 16(9).

PMID: 39339264 PMC: 11435308. DOI: 10.3390/pharmaceutics16091228.


Cellular Output and Physicochemical Properties of the Membrane-Derived Vesicles Depend on Chemical Stimulants.

Shrestha D, Bahasoan Y, Eggeling C ACS Appl Mater Interfaces. 2024; 16(37):48982-48992.

PMID: 39250321 PMC: 11420866. DOI: 10.1021/acsami.4c07234.


Advances in nano-immunotherapy for hematological malignancies.

Xu J, Liu W, Fan F, Zhang B, Sun C, Hu Y Exp Hematol Oncol. 2024; 13(1):57.

PMID: 38796455 PMC: 11128130. DOI: 10.1186/s40164-024-00525-3.


Cell Membrane-Coated Biomimetic Nanoparticles in Cancer Treatment.

Zhang S, Zhang X, Gao H, Zhang X, Sun L, Huang Y Pharmaceutics. 2024; 16(4).

PMID: 38675192 PMC: 11055162. DOI: 10.3390/pharmaceutics16040531.


Association of a decreased platelet count with poor survival in patients with adult secondary hemophagocytic lymphohistiocytosis.

Cheng W, Xu J, Shu Y, Qiu H, Yin G Ann Hematol. 2024; 103(4):1159-1166.

PMID: 38378930 DOI: 10.1007/s00277-024-05663-6.


References
1.
Zhang W, Gou P, Dupret J, Chomienne C, Rodrigues-Lima F . Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play. Transl Oncol. 2021; 14(10):101169. PMC: 8273223. DOI: 10.1016/j.tranon.2021.101169. View

2.
Griffin G, Shenoi S, Hughes G . Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020; 34(4):101515. DOI: 10.1016/j.berh.2020.101515. View

3.
Henter J, Arico M, Egeler R, Elinder G, Filipovich A, Gadner H . Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100(7):2367-73. DOI: 10.1182/blood-2002-01-0172. View

4.
Trottestam H, Horne A, Arico M, Egeler R, Filipovich A, Gadner H . Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011; 118(17):4577-84. PMC: 3208276. DOI: 10.1182/blood-2011-06-356261. View

5.
Li R, He Y, Zhu Y, Jiang L, Zhang S, Qin J . Route to Rheumatoid Arthritis by Macrophage-Derived Microvesicle-Coated Nanoparticles. Nano Lett. 2018; 19(1):124-134. DOI: 10.1021/acs.nanolett.8b03439. View